Skip to main content Accessibility help
×
Home
Hostname: page-component-56f9d74cfd-p4n5r Total loading time: 0.814 Render date: 2022-06-25T23:34:03.775Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

13 - Clozapine

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

Many clinicians not trained in the use of plasma antipsychotic levels are still familiar with the concept that levels are used commonly during clozapine treatment [2]. Clozapine occupies a special place in the management of severely mentally ill patients as it is the only effective antipsychotic for treatment-resistant schizophrenia, and for schizophrenia patients with aggression, polydipsia, or a history of suicidality [3]. Approximately one-third of schizophrenia patients are treatment resistant, but one limitation to clozapine use is prescriber fear of adverse effects, or lack of comfort with managing clozapine’s spectrum of relatively unusual adverse effects [4, 5].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 249 - 266
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 24, 7078.
Best-Shaw, L., Gudbrandsen, M., Nagar, J., et al. (2014). Psychiatrists’ perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring. Ther Drug Monit, 36, 486493.
Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.
Cohen, D. (2014). Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand, 130, 154155.
Gee, S., Vergunst, F., Howes, O., et al. (2014). Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand, 130, 1624.
Conley, R. R., Tamminga, C. A., Bartko, J. J., et al. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry, 155, 914920.
Samara, M. T., Dold, M., Gianatsi, M., et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73, 199210.
Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789796.
Conley, R. R., Tamminga, C. A., Kelly, D. L., et al. (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry, 46, 7377.
Conley, R. R., Kelly, D. L., Richardson, C. M., et al. (2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol, 23, 668671.
Meltzer, H. Y., Bobo, W. V., Roy, A., et al. (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry, 69, 274285.
Potkin, S. G., Bera, R., Gulasekaram, B., et al. (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry, 55 Suppl B, 133136.
Kronig, M. H., Munne, R. A., Szymanski, S., et al. (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry, 152, 179182.
Renwick, A. C., Renwick, A. G., Flanagan, R. J., et al. (2000). Monitoring of clozapine and norclozapine plasma concentration–time curves in acute overdose. J Toxicol Clin Toxicol, 38, 325328.
Takeuchi, H., Powell, V., Geisler, S., et al. (2016). Clozapine administration in clinical practice: once daily versus divided dosing. Acta Psychiatr Scand, 134, 234240.
Li, C. H., Stratford, R. E., Jr., Velez de Mendizabal, N., et al. (2014). Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. J Transl Med, 12, 203.
Asmal, L., Flegar, S. J., Wang, J., et al. (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006625.
Vanasse, A., Blais, L., Courteau, J., et al. (2016). Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand, 134, 374384.
Stahl, S. M. (2016). Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr, 21, 271275.
Meltzer, H. Y., Elkis, H., Vanover, K., et al. (2012). Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res, 141, 144152.
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279302.
Schwieler, L., Linderholm, K. R., Nilsson-Todd, L. K., et al. (2008). Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci, 83, 170175.
Sur, C., Mallorga, P. J., Wittmann, M., et al. (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proceedings of the National Academy of Sciences of the United States of America, 100, 1367413679.
Barak, S. and Weiner, I. (2011). The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol, 14, 12331246.
McKinzie, D. L. and Bymaster, F. P. (2012). Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol, 233265.
Karmacharya, R., Lynn, S. K., Demarco, S., et al. (2011). Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus. Brain Res, 1393, 9199.
Pei, Y., Asif-Malik, A., and Canales, J. J. (2016). Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry, and clinical implications. Front Neurosci, 10, 148.
Dedic, N., Jones, P. G., Hopkins, S. C., et al. (2019). SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther, 371, 114.
Haslemo, T., Eikeseth, P. H., Tanum, L., et al. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol, 62, 10491053.
Khorassani, F., Kaufman, M., and Lopez, L. V. (2018). Supratherapeutic serum clozapine concentration after transition from traditional to electronic cigarettes. J Clin Psychopharmacol, 38, 391392.
Schoretsanitis, G., Kane, J. M., Ruan, C. J., et al. (2019). A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol, 12, 603621.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.
Leung, J. G., Nelson, S., Takala, C. R., et al. (2014). Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother, 48, 801805.
Clark, S. R., Warren, N. S., Kim, G., et al. (2018). Elevated clozapine levels associated with infection: a systematic review. Schizophr Res, 192, 5056.
Siskind, D., Honer, W. G., Clark, S., et al. (2020). Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci, 45, 2.
Meyer, J. M., Proctor, G., Cummings, M., et al. (2017). Ciprofloxacin and clozapine – a potentially fatal but underappreciated interaction. Case Rep Psychiatry, 5606098, 17.
Perry, P. J., Miller, D. D., Arndt, S. V., et al. (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry, 148, 231235.
Llorca, P. M., Lancon, C., Disdier, B., et al. (2002). Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci, 27, 3037.
Conley, R. R., Carpenter, W. T., Jr., and Tamminga, C. A. (1997). Time to clozapine response in a standardized trial. Am J Psychiatry, 154, 12431247.
Kapur, S., Zipursky, R., Jones, C., et al. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157, 514520.
Farde, L., Wiesel, F. A., Halldin, C., et al. (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry, 45, 7176.
Farde, L., Wiesel, F. A., Nordstrom, A. L., et al. (1989). D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology, 99 S2831.
Wiesel, F. A., Farde, L., Nordstrom, A. L., et al. (1990). Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry, 14, 759767.
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318325.
Remington, G., Agid, O., Foussias, G., et al. (2013). Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl), 225, 505518.
Paz, E., Bouzas, L., Hermida, J., et al. (2008). Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem, 41, 603606.
Hiemke, C., Baumann, P., Bergemann, N., et al. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry, 44, 195235.
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432438.
Nielsen, J. and Meyer, J. M. (2012). Risk factors for ileus in patients with schizophrenia. Schizophr Bull, 38, 592598.
Meyer, J. M. and Cummings, M. A. (2014). Lubiprostone for treatment-resistant constipation associated with clozapine use. Acta Psychiatr Scand, 130, 7172.
Food and Drug Administration (2020). FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems. Risk increased at higher doses or when taken with other constipating medicines. FDA Drug Safety Communication (January 28, 2020).
de Leon, J. (2005). Benztropine equivalents for antimuscarinic medication. Am J Psychiatry, 162, 627.
Devinsky, O., Honigfeld, G. and Patin, J. (1991). Clozapine-related seizures. Neurology, 41, 369371.
Pacia, S. V. and Devinsky, O. (1994). Clozapine-related seizures: experience with 5,629 patients. Neurology, 44, 22472249.
Williams, A. M. and Park, S. H. (2015). Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs, 29, 101111.
Acharya, S. and Bussel, J. B. (2000). Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol, 22, 6265.
Malik, S., Lally, J., Ajnakina, O., et al. (2018). Sodium valproate and clozapine induced neutropenia: a case control study using register data. Schizophr Res, 195, 267273.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×